natgillin/translations-raw huggingface dataset:
Hyrimoz is only available as 40 mg pre-filled syringe / pre-filled pen.
Zdravilo Hyrimoz je na voljo samo v 40 mg napolnjeni injekcijski brizgi/napolnjenem injekcijskem peresniku.
Hyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).
Zdravilo Hyrimoz je indicirano za zdravljenje aktivnega artritisa, povezanega z entezitisom pri bolnikih, starih 6 let in več, ki so se neustrezno odzvali ali so intolerantni za običajno zdravljenje
Hyrimoz 40 mg solution for injection in pre-filled syringe adalimumab
Hyrimoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab
The recommended Hyrimoz induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160 mg at week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days) and 80 mg at week 2 (given as two 40 mg injections in one day).
Priporočena shema odmerjanja zdravila Hyrimoz med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivnim ulceroznim kolitisom 160 mg 0. teden (aplicirano kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva dni zapored) in 80 mg 2. teden (aplicirano kot dve 40 mg injekciji v enem dnevu).
Hyrimoz 40 mg solution for injection in single-use pre-filled SensoReady pen Hyrimoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label (SensoReady).
Zdravilo Hyrimoz je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo, v peresniku trikotne oblike s prozornim okencem in oznako (peresnik SensoReady®).
Some patients who experience decrease in their response to Hyrimoz 40 mg every other week may benefit from an increase in dosage to 40 mg Hyrimoz every week or 80 mg every other week.
Nekaterim bolnikom, ki se jim zmanjša odziv na zdravilo Hyrimoz 40 mg vsak drugi teden, lahko koristi povečanje odmerka zdravila Hyrimoz na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Your Hyrimoz single-use pre-filled SensoReady pen
Vaš napolnjeni injekcijski peresnik SensoReady zdravila Hyrimoz za enkratno uporabo
6.8 (4.4, 10.5) per 1,000 patient years among 5,291 adalimumab-treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients).
AS, psoriatičnim artritisom, psoriazo, hidradenitis suppurativa, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95 % interval zaupanja) 6,8 (4,4; 10,5) na 1000 bolnikov let med 5291 bolniki, ki so dobivali adalimumab, in 6,3 (3,4; 11,8) na 1000 bolnikov let med 3444 kontrolnimi bolniki (pri prvih je zdravljenje z adalimumabom mediano trajalo 4,0 mesece in pri drugih 3,8 meseca).
The recommended Hyrimoz dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one day).
Priporočena shema odmerjanja zdravila Hyrimoz pri odraslih bolnikih s hidradenitis suppurativa (HS) je 160 mg na 1. dan (apliciranov obliki štirih 40 mg injiciranj na dan ali z dvema 40 mg injiciranjema na dan dva dni zapored), ki mu sledi 80 mg dva tedna kasneje na 15. dan (apliciranov obliki dveh 40 mg injiciranj v enem dnevu).
The recommended dose of Hyrimoz for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the initial dose.
Priporočeno odmerjanje zdravila Hyrimoz za odrasle bolnike je začetni odmerek 80 mg subkutano in nato 40 mg subkutano vsak drugi teden, začenši en teden po začetnem odmerku.
Hyrimoz 40 mg solution for injection (injection) in pre-filled syringe is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution.
Zdravilo Hyrimoz 40 mg raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Hyrimoz is supplied in a single-use clear type I glass syringe with a stainless steel needle with a needle guard with finger flange, rubber needle cap and plastic plunger rod, containing 0.8 ml of solution.
Zdravilo Hyrimoz je na voljo v injekcijski brizgi za enkratno uporabo iz prozornega stekla tipa I z iglo iz nerjavečega jekla s ščitnikom za iglo z držalom, z gumijastim pokrovčkom za iglo in s plastičnim batom, ki vsebuje 0,8 ml raztopine.
Hyrimoz can reduce the number of nodules and abscesses you have, and the pain that is often associated with the disease.
Zdravilo Hyrimoz lahko zmanjša število vozličev in ognojkov, ki jih imate.
There is no relevant use of Hyrimoz in children aged less than 2 years in this indication.
Uporaba zdravila Hyrimoz pri otrocih, mlajših od 2 let, za to indikacijo ni primerna.
Hyrimoz 40 mg solution for injection (injection) in pre-filled pen is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution.
Zdravilo Hyrimoz 40 mg raztopina za injiciranje (injekcija) v napolnjenem injekcijskem peresniku je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Check with your doctor before you receive any vaccines.
Preden opravite kakršnokoli cepljenje, se posvetujte z zdravnikom.
Vertigo and visual impairment may occur following administration of Hyrimoz (see section 4.8).
Po dajanju zdravila Hyrimoz se lahko pojavita vrtoglavica in poslabšanje vida (glejte poglavje 4.8).
The recommended dose of Hyrimoz for adult patients with uveitis is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose.
Priporočeni začetni odmerek zdravila Hyrimoz za odrasle bolnike z uveitisom je 80 mg, čemur sledi 40 mg odmerek vsak drugi teden, ki se ga začne dajati en teden po začetnem odmerku.
Hyrimoz is administered via subcutaneous injection.
Zdravilo Hyrimoz se odmerja v obliki subkutane injekcije.
Hyrimoz dose for paediatric patients with uveitis Patient weight
Odmerjanje zdravila Hyrimoz pri pediatričnih bolnikih z uveitisom
• You might get infections more easily while you are receiving Hyrimoz treatment.
• Med zdravljenjem z zdravilom Hyrimoz se lahko poveča dovzetnost za okužbe.
Hyrimoz should be used with caution in patients with mild heart failure (NYHA class I/II).
Pri bolnikih z blagim srčnim popuščanjem (razred I/II po NYHA) je treba zdravilo Hyrimoz uporabljati previdno.
Treatment with Hyrimoz must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.
Pri bolnikih, ki se jim na novo pojavijo simptomi kongestivnega srčnega popuščanja ali se jim takšni simptomi poslabšajo, je treba zdravljenje z zdravilom Hyrimoz prekiniti.
During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of
V kontroliranih delih preskušanj, ki podpirajo vlogo za pridobitev dovoljenja za promet adalimumaba pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za
The recommended dose of Hyrimoz is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg every other week starting one week later.
Priporočeno odmerjanje zdravila Hyrimoz je začetni odmerek 8 mg (kot dve 40-mg injekciji v enem dnevu), čemur sledi 40 mg vsak drugi teden z začetkom en teden po začetnem odmerku.
Hyrimoz is contraindicated in moderate to severe heart failure (see section 4.3).
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Hyrimoz kontraindicirano (glejte poglavje 4.3).
• low blood measurements for platelets;
• nizke krvne vrednosti za trombocite;
Hyrimoz therapy should not be continued in patients failing to respond within this time period.
Pri bolnikih, ki se v tem času ne odzovejo, zdravljenja z zdravilom Hyrimoz ni priporočljivo nadaljevati.
When needed (for example when you are travelling), Hyrimoz may be stored at room temperature (up to 25°C) for a maximum period of 14 days - be sure to protect it from light.
Če je potrebno (na primer kadar potujete), lahko zdravilo Hyrimoz hranite pri sobni temperaturi
Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.
40 mg vsak drugi teden Podatki, ki so na voljo, kažejo, da je klinični odziv ponavadi dosežen v 12 tednih zdravljenja.
Hyrimoz 40 mg solution for injection in pre-filled syringe:
Hyrimoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi adalimumab
Your doctor will check whether Actos is working 3 to 6 months after you start taking it.
Zdravnik bo preveril, ali zdravilo Actos deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
The estimated volume of distribution in humans is 0.25 L/kg.
Ocenjeni volumen porazdelitve pri človeku je 0,25 l/kg.
If you experience any of these, especially if you are over the age of 65, seek medical advice straight away.
Če opazite kar koli od tega, še posebej če ste starejši od 65 let, nemudoma poiščite zdravniško pomoč.
You can usually continue to take other medicines whilst you are being treated with Actos.
Običajno lahko še naprej jemljete druga zdravila, medtem ko se zdravite z zdravilom Actos.
- if you have or have ever had bladder cancer.
- če imate ali ste kdaj imeli raka sečnega mehurja.
FOR CALENDARISED PACKS:
ZA KOLEDARSKA PAKIRANJA:
What Actos is and what it is used for
Kaj je zdravilo Actos in za kaj ga uporabljamo
The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.
Najvišji poročani odmerek 120 mg/dan štiri dni, zatem pa 180 mg/dan sedem dni, ni bil povezan s kakršnimi koli simptomi.
The safety and efficacy of Actos in children and adolescents under 18 years of age have not been established.
Varnost in učinkovitost zdravila Actos pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
Priporočljivo je, da imate pri sebi nekaj kock sladkorja, bonbone, piškote ali sladek sadni sok.
Take Actos daily as prescribed.
Zdravilo Actos jemljite vsak dan, kakor vam je predpisano.
Tell your doctor if - you are, you think you might be or are planning to become pregnant.
Povejte zdravniku - če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev.
nausea or vomiting).
siljenje na bruhanje ali bruhanje).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zdravili, ki jih lahko dobite brez recepta.
See leaflet for further information.
Za nadaljnje informacije glejte navodilo.
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss,
- če ste imeli diabetično ketoacidozo (zaplet sladkorne bolezni, ki povzroča hitro hujšanje,
Actos helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.
Zdravilo Actos pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
This study showed an increase in reports of heart failure; however this did not lead to an increase in mortality in this study.
Ta študija je pokazala povečanje poročil srčnega popuščanja; vendar to ni vodilo k dvigu smrtnosti v tej študiji.
Pioglitazone is contraindicated in patients with:
Pioglitazon je kontraindiciran pri bolnikih:
In particular, patients have experienced the following serious side effects:
Pri bolnikih so še posebej poročali o naslednjih resnih neželenih učinkih:
not known (frequency cannot be estimated from the available data) - increase in liver enzymes - allergic reactions
neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - povišanje vrednosti jetrnih encimov - alergijske reakcije
Immune System Disorders hypersensitivity and allergic reactions1
Bolezni imunskega sistema preobčutljivostne in alergijske reakcije1
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2-5%.
Date of first authorisation: 13/10/2000 Date of latest renewal: 31/08/2010
Datum zadnjega podaljšanja: 31. avgust 2010
If you take Actos with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).
Če zdravilo Actos jemljete z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost krvnega sladkorja pade pod normalno raven (hipoglikemija).
Other medicines and Actos
Druga zdravila in zdravilo Actos
In some cases weight increase may be a symptom of cardiac failure; therefore weight should be closely monitored.
V nekaterih primerih je povečanje telesne mase lahko simptom srčnega popuščanja; zato je treba telesno maso skrbno spremljati.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these.
Vendar pa nekatera zdravila še posebej verjetno lahko vplivajo na količino sladkorja v krvi: - gemfibrozil (uporablja se za zniževanje holesterola) - rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb) Obvestite zdravnika ali farmacevta, če jemljete katero od teh zdravil.
Use in children and adolescents under 18 years is not recommended.
Otroci in mladostniki Uporaba tega zdravila pri bolnikih, mlajših od 18 let, ni priporočljiva.
de la Industria 30 28108 Alcobendas (Madrid) Spain
de la Industria 30 28108 Alcobendas (Madrid) Španija
de la Industria 30, 28108 Alcobendas (Madrid), Spain
de la Industria 30, 28108 Alcobendas (Madrid), Španija
- if you have liver disease.
- če imate bolezen jeter.
If you forget to take Actos
Če ste pozabili vzeti zdravilo Actos
Actos has no or negligible influence on the ability to drive and use machines.
Zdravilo Actos nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Before you start taking Actos you will have a blood sample taken to check your liver function.
Pred začetkom jemanja zdravila Actos vam bodo odvzeli vzorec krvi, da se preveri delovanje jeter.
Your doctor will ask you to have blood tests periodically during treatment with Actos.
Zdravnik vas bo v času zdravljenja z zdravilom Actos naročal na redne preiskave krvi.
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, acetylsalicylic acid, statins, fibrates).
Skoraj vse osebe (95%) so prejemale kardiovaskularna zdravila (zaviralce adrenergičnih receptorjev beta, zaviralce angiotenzinske konvertaze (zaviralce ACE), antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, acetilsalicilno kislino, statine, fibrate).
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
Ni jasno, ali obstaja neposredna povezava med pioglitazonom in makularnim edemom, vendar pa morajo biti zdravniki pozorni na možnost makularnega edema, če bolnik poroča o motnjah vidne ostrine; razmisliti je treba o pregledu pri oftalmologu.
However if you miss a dose, just carry on with the next dose as normal.
Če ste pozabili vzeti odmerek, nadaljujte z naslednjim odmerkom kot sicer.
These reactions include anaphylaxis, angioedema, and urticaria.
Te reakcije vključujejo anafilaksijo, angioedem in urtikarijo.
Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Ireland.
Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Irska Lilly S.A., Avda.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Actos.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila Actos posvetujte s svojim zdravnikom.
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
Tudi epidemiološke študije kažejo malo večje tveganje za rak mehurja pri bolnikih s sladkorno boleznijo, zdravljenih s pioglitazonom, čeprav pri vseh študijah povečanje tveganja ni bilo statistično signifikantno.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
Zdravilna učinkovina pioglitazon je indicirana kot drugi ali tretji izbor zdravljenja sladkorne bolezni tipa 2, kot je opisano spodaj:
If you stop taking Actos
Če ste prenehali jemati zdravilo Actos
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually.
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt ali simptomatsko koronarno arterijsko bolezen ali v primeru starejših bolnikov), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma zviševati.
What Actos is and what it is used for What you need to know before you take Actos How to take Actos
Kaj je zdravilo Actos in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Actos Kako jemati zdravilo Actos Možni neželeni učinki
These findings were observed across species at plasma concentrations ≤ 4 times the clinical exposure.
Te ugotovitve so potrdila opažanja pri vseh vrstah pri plazemskih koncentracijah  4-kratne plazemske koncentracije pri klinični izpostavitvi.
When Actos is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.
Če boste zdravilo Actos jemali skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, če morate jemati nižje odmerke teh zdravil.
If you are following a special diet for diabetes, you should continue with this while you are taking Actos.
Če ste na posebni dieti za sladkorno bolezen, morate z dieto med jemanjem zdravila Actos nadaljevati.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, p=0.029).
O primerih raka sečnega mehurja so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12.506 bolnikov, 0,15%) kot v kontrolnih skupinah (7 primerov od 10.212 bolnikov, 0,07%) HR=2,64 (95% IZ 1,11-6,31, p=0,029).
What you need to know before you take Actos Do not take Actos
Kaj morate vedeti, preden boste vzeli zdravilo Actos
Actos should be used every day to work properly.
Za pravilno delovanje morate zdravilo Actos jemati vsak dan.
The other side effects that have been experienced by some patients taking Actos are:
Drugi neželeni učinki, ki so se pojavili pri nekaterih bolnikih, ki so jemali zdravilo Actos, so:
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
O edemih so poročali pri 6-9% bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
If you have the impression that the effect of Actos is too weak, talk to your doctor.
Če menite, da je učinek zdravila Actos prešibak, se posvetujte z zdravnikom.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups.
Ko so izločili bolnike, ki so bili v času diagnoze rak mehurja preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06%) raka mehurja pri pioglitazonu in 2 primera (0,02%) v kontrolnih skupinah.
The other side effects that have been experienced by some patients when Actos is taken with other antidiabetic medicines are:
Drugi neželeni učinki, ki so se pojavili pri nekaterih bolnikih, ki so jemali zdravilo Actos skupaj z drugimi antidiabetičnimi zdravili, so:
At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
Po dveh letih je nadzor glikemije (definiran kot HbA1c < 8,0%) vztrajal pri 69% bolnikov, zdravljenih s pioglitazonom, v primerjavi s 50% bolnikov, ki so prejemali gliklazid.
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Actos, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, o tem nemudoma obvestite svojega zdravnika ali farmacevta.
If ALT levels are increased to 3 x upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible.
Če se med zdravljenjem s pioglitazonom ravni ALT zvišajo do 3-kratne zgornje meje normalnih vrednosti, je treba ravni jetrnih encimov čim prej ponovno kontrolirati.
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.
2 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri drugih hipoglikemičnih učinkovinah.
If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.
V primeru pojava resne alergijske reakcije, ki vključuje koprivnico in otekanje obraza, ustnic, jezika ali žrela, kar lahko povzroči težave z dihanjem ali s požiranjem, takoj prenehajte z jemanjem tega zdravila in nemudoma poiščite zdravniško pomoč.
- if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Actos - če ste alergični na pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45%, v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini zdravljeni s pioglitazonom.